Hims & Hers Health (NYSE:HIMS) reported third-quarter earnings that surpassed analyst expectations and raised its full-year ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...

An injection pen of Zepbound, Eli Lilly’s weight-loss drug ... week reported a rare $1.5 billion sales miss for its ...

Size means little in light of this company's prospects.

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...

Eli Lilly and its investors this past week learned a hard lesson: The sky is no longer the limit when it comes to sales of its blockbuster glucagon-like peptide 1 (GLP-1) drugs for diabetes and ...

US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...